MIRAGEN THERAPEUTICS, INC. MGEN Income Statement

Miragen therapeutics, inc. (MGEN)

Income statement / Quarterly

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Sep'13	Jun'13
Collaboration revenue
-	-	-	-	-	-	-	-	-	-	-	-	10	335	715	847	917	-	-	-	-	-	-	-	-	-	-
Grant revenue
-	-	-	-	-	-	-	-	-	-	-	-	452	174	221	268	0	-	-	-	-	-	-	-	-	-	-
Revenue:
Total revenue
828	880	695	2,514	372	476	944	2,182	4,784	-	1,631	718	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total revenue
-	-	-	-	-	-	-	-	-	-	-	-	462	509	936	1,115	917	658	501	734	645	654	1,301	1,274	1,091	983	1,102
Operating expenses:
Cost of revenue
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	457	577	678	760	781	900	954	731	713	603
Research and development
6,103	8,417	9,027	8,599	8,751	8,234	7,399	8,375	6,413	4,998	5,018	5,487	4,120	3,906	2,965	3,355	3,466	455	253	194	100	79	105	128	35	46	22
Selling and marketing
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	755	796	574	434	416	169	66	66	99	67
General and administrative
2,723	2,534	2,898	2,857	3,357	2,695	2,696	2,668	2,990	2,548	2,502	2,581	3,281	2,517	2,053	1,210	992	1,948	2,003	1,778	1,963	1,734	1,760	2,937	426	435	470
Total operating expenses
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3,629	-	-	-	-	-	-	-	-
Total operating expenses
8,826	10,951	11,925	11,456	12,108	10,929	10,095	11,043	9,403	7,546	7,520	8,068	7,401	6,423	5,018	4,565	4,458	-	-	3,224	3,257	-	2,934	4,085	1,258	1,295	1,163
Loss from operations
-7,998	-10,071	-11,230	-8,942	-11,736	-10,453	-9,151	-8,861	-4,619	-6,354	-5,889	-7,350	-6,939	-5,914	-4,082	-3,450	-3,541	-2,957	-3,128	-2,490	-2,612	-2,256	-1,633	-2,811	-167	-311	-60
Other income (expense):
Interest and other income
95	123	204	275	339	364	362	361	167	158	113	102	30	16	7	9	7	-	-	-	-	-	-	-	-	-	-
Interest and other expense
141	170	204	229	232	228	222	214	209	190	58	64	71	76	78	83	89	-	-	-	-	-	-	-	-	-	-
Interest expense
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	23	24	72	22	2	4	478	539	567	479
Net Income (Loss) Attributable to Parent
-8,044	-10,118	-11,230	-8,896	-11,629	-10,317	-9,011	-8,714	-4,661	-6,386	-5,834	-7,312	-6,980	-5,974	-4,153	-3,524	-3,623	-2,980	-3,152	-2,562	-2,634	-2,258	-1,637	-3,289	-706	-939	-629
Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, before Tax
0	-3	-8	9	5	3	-10	4	0	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Comprehensive loss
-8,044	-10,121	-11,238	-8,887	-11,624	-10,314	-9,021	-8,710	-4,661	-	-5,834	-7,312	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accretion of redeemable convertible preferred stock to redemption value
-	-	-	-	-	-	-	-	-	0	0	0	5	36	13	12	-12	-	-	-	-	-	-	-	-	-	-
Net loss
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-879	-539
Dividend to member unit holder of Myeloma Health LLC
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	60	90
Net loss
-8,044	-10,118	-11,230	-8,896	-11,629	-10,317	-9,011	-8,714	-4,661	-6,386	-5,834	-7,312	-6,985	-5,986	-4,166	-3,536	-3,635	-	-	-	-	-	-	-	-	-	-
Net loss per share, basic and diluted (in dollars per share)
-0.18	-0.31	-0.36	-0.29	-0.38	-0.34	-0.29	-0.29	-0.18	-0.17	-0.27	-0.34	-0.60	-9.83	-6.92	-5.88	-5.58	-14.39	-5.85	-0.33	-0.45	-43.84	-0.40	-4.73	-3.53	-0.35	-0.24
Weighted-average shares used to compute basic and diluted net loss per share (in shares)
45,476	32,394	31,081	30,983	30,886	30,899	30,723	30,295	26,483	22,440	21,572	21,409	11,555	601	601	601	651	-11,962	541	7,785	5,793	-4,356	4,062	695	200	2,672	2,591
Collaboration revenue
Total revenue
681	837	625	2,498	348	435	814	1,368	4,756	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Grant revenue
Total revenue
147	43	70	16	24	41	130	814	28	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-